Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Interferon Treatment Eradicates a New Human Coronavirus in a Culture Model

By BiotechDaily International staff writers
Posted on 06 Mar 2013
A recently recognized human coronavirus was treated successfully in an in vitro model based on human bronchial epithelial tissue, which reduces fears that the virus might be capable of setting off a worldwide respiratory disease pandemic.

The recent emergence of a novel human coronavirus (HCoV-EMC) in the Middle East raised considerable concerns, as it was found to be associated with severe acute pneumonia, renal failure, and fatal outcome and thus resembled the clinical presentation of severe acute respiratory syndrome (SARS) observed in 2002 and 2003. Like SARS-CoV, HCoV-EMC is of zoonotic origin and closely related to bat coronaviruses.

To get a handle on this potentially fatal pathogen, investigators at Kantonal Hospital (St. Gallen, Switzerland) developed an in vitro model based on human bronchial epithelial cells, which are highly susceptible to HCoV-EMC infection and in which the virus is able to multiply at a faster initial rate than the SARS virus. The investigators employed advanced genomic research tools such as reverse transcription (RT)-PCR and RNAseq data to experimentally determine the identity of seven HCoV-EMC subgenomic mRNAs.

Results published in the February 19, 2013, online edition of the journal mBio revealed that while the human bronchial epithelial cells were readily responsive to type I and type III interferon (IFN), neither a pronounced inflammatory cytokine nor any detectable IFN responses were found following HCoV-EMC infection, suggesting that innate immune evasion mechanisms and possible IFN antagonists of the virus were operational in the human host. On the other hand, type I and type III IFN were found to efficiently reduce HCoV-EMC replication in the human cell cultures, providing a possible treatment option in cases of suspected HCoV-EMC infection.

"Surprisingly, this coronavirus grows very efficiently on human epithelial cells," said senior author Dr. Volker Thiel, a senior research fellow at Kantonal Hospital. "The other thing we found is that the viruses (HCoV-EMC, SARS, and the common cold virus) are all similar in terms of host responses: they do not provoke a huge innate immune response. We do not know whether the cases we observe are the tip of the iceberg, or whether many more people are infected without showing severe symptoms."

Related Links:
Kantonal Hospital



Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.